Janux Therapeutics (JANX) Receivables - Accured (2021 - 2025)
Historic Receivables - Accured for Janux Therapeutics (JANX) over the last 5 years, with Q3 2025 value amounting to $6.3 million.
- Janux Therapeutics' Receivables - Accured rose 4000.0% to $6.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.3 million, marking a year-over-year increase of 4000.0%. This contributed to the annual value of $5.4 million for FY2024, which is 14545.45% up from last year.
- Per Janux Therapeutics' latest filing, its Receivables - Accured stood at $6.3 million for Q3 2025, which was up 4000.0% from $5.7 million recorded in Q2 2025.
- In the past 5 years, Janux Therapeutics' Receivables - Accured registered a high of $28.0 million during Q3 2021, and its lowest value of $3000.0 during Q2 2021.
- Moreover, its 5-year median value for Receivables - Accured was $2.0 million (2023), whereas its average is $4.0 million.
- Within the past 5 years, the most significant YoY rise in Janux Therapeutics' Receivables - Accured was 990000.0% (2022), while the steepest drop was 9892.86% (2022).
- Janux Therapeutics' Receivables - Accured (Quarter) stood at $200000.0 in 2021, then soared by 250.0% to $700000.0 in 2022, then skyrocketed by 214.29% to $2.2 million in 2023, then skyrocketed by 145.45% to $5.4 million in 2024, then grew by 16.67% to $6.3 million in 2025.
- Its last three reported values are $6.3 million in Q3 2025, $5.7 million for Q2 2025, and $5.6 million during Q1 2025.